Our
Leadership

Dr. Gerberding joined the FNIH as CEO on May 16, 2022. She served before that as Chief Patient Officer and Executive Vice President, Population Health & Sustainability, at Merck & Co., Inc., where she was responsible for patient engagement, corporate social responsibility, Environmental/Social/Governance issues, and other functions. Formerly, Dr. Gerberding oversaw Global Public Policy and Strategic Communications for the company. She joined Merck in 2010 as President of Merck Vaccines and was instrumental in increasing access to the company’s vaccines to people around the world.

Previously, Dr. Gerberding was Director of the U.S. Centers for Disease Control and Prevention (CDC), where she led the agency through 40 emergency responses to public health crises, including the SARS-CoV-1 outbreak. She serves on the boards of the Mayo Clinic, National Health Council, Cerner Corporation, Case Western Reserve University, AfterNext HealthTech, and HilleVax. She also co-chairs the Center for Strategic and International Studies Commission on Strengthening America’s Health Security.

Dr. Gerberding received her undergraduate and M.D. degrees from Case Western Reserve University and a Master of Public Health at the University of California, Berkeley. She completed her internship and residency in Internal Medicine and fellowship in Clinical Pharmacology and Infectious Diseases at the University of California, San Francisco, where she is currently an Adjunct Associate Professor of Medicine.

Dr. Stacey Adam is a Vice President at the FNIH, leading many public-private partnerships, such as Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV); the Biomarkers Consortium (Cancer and Metabolic Disorders Steering Committees) and their projects; Accelerating Medicines Partnerships (AMPs)-Common Metabolic Diseases, Heart Failure, and Parkinson’s Disease, Partnership for Accelerating Cancer Therapies (PACT); and the Lung Master protocol (Lung-MAP) clinical trial.

Prior to FNIH, Dr. Adam was a Manager at Deloitte Consulting in the Federal Life Sciences and Healthcare Strategy practice where she supported many federal and non-profit client projects. Before Deloitte, Dr. Adam conducted her postdoctoral fellowship at Stanford University School of Medicine, where she was both an NIH and American Cancer Society supported fellow, and she earned her Ph.D. in Pharmacology with a Certificate in Mammalian Toxicology from Duke University.

David A. Carmel joined the FNIH as its first Chief Growth and Innovation Officer in September 2022. He serves as a key member of the executive leadership team, leading the FNIH communications and events divisions, and helping to expand the foundation’s scale and impact.

Prior to joining the FNIH, Mr. Carmel served as Senior Vice President, Public Affairs and Communications, at eGenesis, a gene-editing company. He was responsible for all public and investor relations and led the company’s $125 million Series C financing from leading institutional investors in healthcare. Earlier, he was Vice President, Medical Affairs and Strategic Alliances, at Altara Biotherapeutics, and Co-Founder and Principal of Carmel Asset Management, an investment partnership where he was responsible for life science investments. He has also held positions in public affairs and business development at StemCyte, Pfizer, and Johnson & Johnson. He served as a White House Fellow from 2002 to 2003.

Mr. Carmel was appointed by Governor Andrew Cuomo to the New York Life Science Advisory Board. He is a Henry Crown Fellow of the Aspen Institute, a former member of the New York State Spinal Cord Injury Research Board, and a founding board member of the New York Stem Cell Foundation. He worked on the California Stem Cell Research and Cures Initiative, which provided $3 billion to fund stem cell research. He earned a bachelor’s degree, magna cum laude, from Harvard College and an MBA with a certificate in health care from the Stanford Graduate School of Business.

Love Collins, III, joined the FNIH as Vice President of Advancement on May 13, 2024. He leads the FNIH’s efforts to expand its portfolio of resources and help accelerate the launch of new collaborative biomedical research programs and related scientific efforts.

With more than 30 years of experience in both the public and private sectors, Mr. Collins has extensive expertise in fundraising, strategic planning, and organizational development with particular emphasis in biomedical research and health science philanthropy. He has successfully raised over $500 million for a diverse range of non-profit organizations.

Mr. Collins served as Vice Chancellor of Development and Alumni Affairs at the University of Tennessee Health Science Center and as Vice President of Development and Communications at the Van Andel Institute, where he raised funds in support of translational science and breakthrough research in cancer, Parkinson’s disease, and epigenetics.

His career includes top leadership roles at institutions such as Dillard University, Benedict College, Howard University, Florida A&M University and Foundation, and the 1996 Atlanta Committee for the Olympic Games, where he served as deputy managing director of operations.

Mr. Collins holds a bachelor’s degree in engineering from the U.S. Military Academy at West Point and an MBA in Finance from Emory University, Goizueta Business School.

Read more about Mr. Collins here

Eva Coyne joined the Foundation for the National Institutes of Health (FNIH) in November of 2004. As Vice President and Controller, she oversees FNIH’s daily finance operations, including accounting, financial reporting, payroll, accounts payable, and accounts receivable. Eva also assists with the Annual Budget and Year End forecasts.

Eva is originally from Santiago, Chile, and she is a certified public accountant and auditor from Universidad Central, where she also obtained a bachelor’s degree in accounting. Her career includes more than 30 years in accounting, finance, and auditing with for-profit and not-for-profit organizations in senior and management roles both in the U.S. and in Chile.

Donald Hill joined the FNIH in August 2017 as the Chief Financial Officer of the Foundation. He brings more than 30 years of financial experience with for-profit and not-for-profit organizations. His experience includes CFO roles with Project HOPE, a global health education and humanitarian organization, and Metabolex (CymaBay Therapeutics), a biopharmaceutical company focused on the discovery and development of new medicines for the treatment of metabolic diseases. His career also includes more than 20 years at Merck & Co., in various Finance and Corporate Development roles. Additionally, he worked with Amneal Enterprises and its associated portfolio companies.

He received his M.S. in Finance and Applied Economics from the Sloan School of Management at the Massachusetts Institute of Technology and his B.A. in Political Economy from the University of California, Berkeley. He also holds the Chartered Financial Analyst (CFA) designation.

Steve Hoffmann is a Vice President in Research Partnerships and Director of the Biomarkers Consortium at the Foundation for the National Institutes of Health (FNIH). He provides strategic planning, programmatic management, and research administration of a multi-faceted portfolio of established and emerging projects within the Biomarkers Consortium and Accelerating Medicines Partnership including projects focused on neuroscience, rare diseases, organ toxicity, infectious disease and other autoimmune and inflammatory diseases.

Steve has a broad background in the academic, government and industry sectors in the field of translational biomarkers, molecular immunology, and precision medicine. Prior to joining FNIH, Steve worked as both a project and product manager, supporting protein diagnostics development at Meso Scale Discovery (MSD). Before MSD, Steve was a scientist in the Transplantation and Autoimmunity Branch of the National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) and led research efforts utilizing immune depletion and co-stimulatory blockade strategies for human renal and islet cell transplant trials. Steve holds a Master of Science degree in Pathology and Laboratory Medicine from the University of North Carolina at Chapel Hill and a Bachelor of Science degree in Biochemistry and Biophysics from the University of Pittsburgh.

Dr. Kamphaus has the dual role of leading FNIH Patient Engagement efforts and providing oversight to the Metabolic Disorders Programs within Translational Sciences. In her role as FNIH’s Patient Engagement lead, Dr. Kamphaus is responsible for establishing best practices for engaging patient voices for meaningful, end-to-end patient involvement in public-private partnerships within FNIH programs. She co-chairs to FNIH Patient Engagement Council, serves on the core committee for FNIH DEIA efforts, and is leading the establishment of a Patient Ambassadors Program.

In her role as the Associate Vice President, Science Partnerships, she is responsible for developing new multi-stakeholder public-private partnerships that include stakeholders at NIH, FDA, non-profits and biopharmaceutical industry. Dr. Kamphaus oversees three target validation programs within
Accelerating Medicines Partnerships in areas of Common Metabolic Diseases, Heart Failure, and Type 2 Diabetes. She also oversees projects under the Metabolic Disorders Biomarkers Consortium, including biomarker qualification efforts in nonalcoholic steatohepatitis (NASH), bone quality, pre-eclampsia, and emerging programs in reproductive health and digital biomarkers.

Dr. Kamphaus is trained in molecular genetics and cell biology and skilled in strategic planning and collaborative program development across basic, translational and patient-centric clinical research. Prior to joining the FNIH, she directed the office of Clinical Protocol Development at the University of Wisconsin-Madison, where she supported development of large clinical trial protocols. Before her work in clinical trials, Dr. Kamphaus was the Director of Collaborative Research at the Crohn’s and Colitis Foundation where she was responsible for developing flagship programs like IBD Plexus, Gut Microbiome, and the IBD Genetics Initiative. Dr. Kamphaus conducted her postdoctoral fellowship at Columbia University. She earned her PhD in Molecular Genetics from The Ohio State University and her Masters degree in Biotechnology from Madurai Kamaraj University, India.

Kevin A. Klock joined the FNIH in October 2015 and serves as Senior Vice President, Chief Operating Officer and General Counsel. In addition to providing overall leadership of the Foundation’s corporate infrastructure and legal strategy, he is co-Chair of WHO Collaborating Center Support for New Coordinating Mechanisms, a series of high-level consortia that provide technical advice and learnings to inform the World Health Organization, policymakers, and the public as a pandemic treaty is negotiated.

Klock holds an appointment at Georgetown University as Adjunct Professor and Scholar at the O’Neill Institute for National and Global Health Law. His scholarship has been published in the Journal for the American Medical Association, The Lancet, Oxford University Press, and others. Klock was formerly Head of Governance and Assistant Secretary for Gavi, the Vaccine Alliance where he played a key role to stand up the International Finance Facility for Immunisation (IFFIm). Prior to this he was with the National Association of Corporate Directors (NACD), which provides research and education to corporate boards.

Klock received his J.D., magna cum laude, from Georgetown and is a member of the bars of the District of Columbia and the United States Supreme Court. He is a graduate of Duke University, received his M.A. from American University, and was Lord Rothermere Scholar at Oxford University.

Jane is the Chief of Staff at the Foundation for the National Institutes of Health. She joined FNIH in June 2022 after a long career at Merck & Co., Inc.

As Chief of Staff, Jane is responsible for supporting pull-through of the FNIH strategy, day-to-day operations of the FNIH CEO’s office and other areas within FNIH, and serving as a liaison to internal and external partners and FNIH Board members.

Prior to joining FNIH, Jane had a long career at Merck in various administrator roles supporting marketing and sales functions. She led the administrative team and worked with the president of Merck Vaccines, helping to increase global access to important vaccines. Jane managed the office of Merck’s Executive Vice President and Chief Patient Officer, overseeing a broad portfolio of responsibilities in support of Merck’s global policy, population health, and patient engagement priorities.

Geralyn is responsible for overseeing all communications activities across FNIH programs. She has a long and distinguished career in health communications having held senior leadership positions in nonprofit organizations and public relations firms. She has experience working across therapeutic and public health areas including oncology, vaccines/immunology, organ donation and transplantation, and neurology among others. Most recently, she was Director, Communications and Marketing at the Alzheimer’s Drug Discovery Foundation (ADDF) leading a team focused on earned media, social media, thought leadership and executive communications. Previously, she held positions of increasing responsibility at several public relations agencies: Ruder Finn, Health Unlimited, Finn Partners, and Cooney Waters. Prior, she was Director of Communications at the Leukemia and Lymphoma Society and the New York Organ Donor Network. Geralyn has received several industry awards and been recognized for effective public relations campaigns and strategies.

Janelle Lewis is the Associate Vice President of Meetings and Events at the Foundation for the National Institutes of Health, where she concurrently serves as the inaugural Chairperson of the FNIH’s Diversity, Equity, Inclusion, and Accessibility initiative. In October 2018, she was included in the Professional Convention Management Association’s “20 in Their Twenties” list of professionals whose influence is rising quickly in the meetings and events industry. Prior to the FNIH, she gained experience at various companies working in entertainment and community event planning. Janelle graduated from the University of North Carolina at Chapel Hill with a B.A. in Communications.

Catherine Master joined the Foundation for the National Institutes of Health in April 2017. As Vice President and Deputy General Counsel, she leads the Legal Department, works with the General Counsel in developing the Foundation’s legal strategy and in supporting Board governance, serves as advisor on legal matters to all departments, and contributes to the Foundation’s overall planning and direction as a member of the Leadership and Management Teams. Ms. Master’s experience includes private legal practice, as well as work in corporate and not-for-profit sectors.

Throughout her career, Ms. Master has worked primarily as a transactions attorney, including at the now Locke Lord law firm. More recently, she managed market access and health economics outcomes research contracting for a multibillion dollar global contract research organization, now a division of Labcorp Drug Development. Before law school, she was a registered nurse providing clinical care at major medical centers. She’s also worked in the recruitment of both nurses and attorneys. Ms. Master received her law degree from The University of Texas School of Law. She also has a B.S. in Nursing and a B.A. in English from Auburn University.

Joseph Menetski is Senior Vice President, Chief Translational Science Officer. He received his Ph.D. from Northwestern University Medical School with Dr. Stephen Kowalczykowski and completed his post-doctoral training at the Laboratory of Molecular Biology, National Institutes of Health (NIH/NIDDK) with Dr. Martin Gellert. He then started his career in industry in 1993 in the Immunopathology Department at Parke-Davis (later Pfizer), where he established a discovery research program in cellular inflammation that eventually transitioned to the molecular study of osteoarthritis. Joseph moved to Merck in 2004. His first position was in the department of Immunology where he initiated an osteoarthritis new targets and biomarker program. While at Merck he has been a member of the Molecular Profiling group, the Knowledge Discovery and Knowledge Management group and finally a Director in Global Competitive Intelligence.

Michael Santos is Senior Vice President, Science Partnerships, and Chief Population Health Science Officer. He is responsible for a portfolio of programs supporting biomedical innovation to improve health and health equity globally. He also directs the GeneConvene Global Collaboration, an initiative advancing informed decision making about the development of genetic biocontrol technology for public health.

Prior to joining the FNIH in 2019, Dr. Santos was at the Bill & Melinda Gates Foundation, where he served as a Deputy Director in the Global Health division accountable for strategy and operations across the Discovery & Translational Sciences, HIV, and TB programs. His responsibilities included developing investment strategies for emerging priorities, leading the team and processes that supported investment making and management, and reporting on team strategy and progress. He was also a Strategy Advisor on the Strategy, Innovation, and Impact team, developing perspectives on the philosophy of philanthropy.

Previously Dr. Santos was a Principal at Boston Consulting Group, where he led projects on malaria, HIV, contraceptive technology, global health regulatory systems, and public radio and contributed to strategies in the energy and environment, health care, industrial goods, consumer, and retail sectors. His first career was astronomy: he holds a Ph.D. from Caltech and was a research fellow at the University of Cambridge and the Space Telescope Science Institute.

As Associate Vice President of Operations, Lesley is responsible for the management and delivery of a broad portfolio of operational activities at the Foundation. These include human resources, information technology, facilities management, administration, and related activities that allow the Foundation and its people to carry out their mission. Since her arrival at the FNIH in November 2021, the primary focus of her work has been on refining, developing, and implementing a human resources strategy and the infrastructure required to attract and retain organizational talent, and positions the FNIH as an organization of choice.

Prior to joining the FNIH, Lesley worked as the director of academic appointments in the Office of the Provost at Georgetown University. As director, she provided leadership and oversight for faculty HR operations and strategy execution for the largest campus at the university. In this role, she advised senior leadership inside and outside the office on faculty affairs policies and related HR business operations, including HRIS system design and optimization, union negotiations and various compliance activities. Lesley holds an M.B.A. from Georgetown University, a M.Sc. from SOAS-University of London, and a B.A. from the University of Redlands.

Dr. Courtney Silverthorn is the Vice President for Strategic Alliances and Innovation at the Foundation for the National Institutes of Health (FNIH). With extensive experience in public-private partnerships and federal technology transfer policy, she is responsible for leading the strategic development and management of the Foundation’s business portfolio across multiple departments. Her previous role at the FNIH was as an Associate Vice President in the Science Partnerships department, where she managed a portfolio of public-private partnerships in Platform Therapeutics, including the Bespoke Gene Therapy Consortium, and served as the Director of the Accelerating Medicines Partnership® (AMP®) program.

Prior to joining the FNIH, Courtney held several positions in the Technology Partnerships Office at the National Institute of Standards and Technology (NIST), including serving as the Acting Director of the office from 2020 to 2021. During her time at NIST, she led technology transfer activities at the agency and was central to the interagency Lab-to-Market initiative. Her interagency policy coordination efforts included serving as a Co-Chair of the National Science and Technology Council’s Lab-to-Market subcommittee and developing and implementing findings from NIST’s Return on Investment Initiative. She also served as a Senior Policy Advisor to the Office of Science and Technology Policy, supporting both Lab-to-Market and Citizen Science, and executed hundreds of technology transfer partnerships at the National Cancer Institute and the Frederick National Laboratory for Cancer Research.

Dr. Silverthorn earned a Ph.D. in Pharmacology from The Johns Hopkins University School of Medicine, a M.S. in Leadership from Washington University in St. Louis, and a B.S. in Biochemistry and Molecular Biology from Sweet Briar College. She has also earned certificates in Biotechnology Enterprise from Johns Hopkins and in Policy Strategy from the Brookings Institution.